1. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors 
Kevin L. Anderson, MHSc, Michael S. Mulvihill, MD, Paul J. Speicher, MD, Babatunde A. Yerokun, MD, Brian C. Gulack, MD, Daniel P. Nussbaum, MD, David H. Harpole, MD, Thomas A. D’Amico, MD, Mark F. Berry, MD, Matthew G. Hartwig, MD 
The Annals of Thoracic Surgery 
Volume 104, Issue 4, Pages (October 2017)
DOI: /j.athoracsur
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Survival for patients with atypical lung carcinoids by nodal status, National Cancer Data Base 2006 to (NA = not applicable.)EstimateOverallNode NegativeNode Positivep Value12-Month survival, %97.3 (95.9–98.7)96.5 (94.5–98.5)98.6 (97–100)60-Month survival, %73.5 (69.2–78.1)82.2 (77.5–87.2)59.8 (52.2–68.6)Median survival, months100.2NA70.7<0.001The 12 and 60-month survival rates are median (IQR) measurements.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Unadjusted survival for patients with pathologically node-positive atypical lung carcinoids by use of adjuvant chemotherapy, National Cancer Data Base 2006 to (Chemo = chemotherapy.)EstimateOverallOperation AloneAdjuvant Chemop Value12-Month survival, %98.6 (97–100)98.4 (96.2–100)98.9 (96.6–100)60-Month survival, %59.8 (52.2–68.6)67.1 (58.3–77.2)47.9 (35.7–64.3)Median survival, months The 12 and 60-month survival rates are median (IQR) measurements.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Survival for pathologically node-negative atypical carcinoids by use of adjuvant chemotherapy, National Cancer Data Base 2006 to (Chemo = chemotherapy; NA = not applicable.)EstimateOverallOperation AloneAdjuvant Chemop Value12-Month survival, %96.5 (94.5–98.5)96.9 (95.1–98.8)86.7 (71.1–100)60-Month survival, %82.2 (77.5–87.2)82.6 (77.7–87.7)73.3 (54–99.5)Median survival, monthsNANANA0.087The 12 and 60-month survival rates are median (IQR) measurements.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Propensity-matched survival for pathologically node-negative atypical carcinoids by use of adjuvant chemotherapy, National Cancer Data Base 2006 to (Chemo = chemotherapy; NA = not applicable.)EstimateOverallOperation AloneAdjuvant Chemop Value12-Month survival, %87.6 (80.4–95.5)87.9 (79.8–96.7)86.7 (71.1–100)60-Month survival, %72.8 (62.2–85.2)72.3 (60–87.2)73.3 (54–99.5)Median survival, months NA0.54The 12 and 60-month survival rates are median (IQR) measurements.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

6. Fig 5
Propensity-matched survival for pathologically node-positive atypical carcinoids by use of adjuvant chemotherapy, National Cancer Data Base 2006 to (Chemo = chemotherapy.)EstimateOverallOperation AloneAdjuvant Chemop Value12-Month survival, %98.3 (96.4–100)97.7 (94.5–100)98.9 (96.6–100)60-Month survival, %60.9 (52.4–70.7)72.5 (62.4–84.3)47.9 (35.7–64.3)Median survival, months The 12 and 60-month survival rates are median (IQR) measurements.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions